In agreement with a previous targeted sequencing study (Tennenbaum et al., 2017), the mutation burden of VHL, which is the main hallmark of ccRCC, showed no differences between survivors and nonsurvivors, supporting its role only during early stages of tumorigenesis (Mandriota et al., 2002; Mitchell et al., 2018). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.